A5011633716- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Endometriosis Research and Treatment
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Immune cells in cancer
- Endometrial and Cervical Cancer Treatments
- Uterine Myomas and Treatments
Albany Medical Center Hospital
2024
Brigham and Women's Hospital
2022-2024
Harvard University
2022
Programmed cell death 1 (PD-1) is a premier cancer drug target for immune checkpoint blockade (ICB). Because PD-1 receptor inhibition activates tumor-specific T-cell immunity, research has predominantly focused on T-cell-PD-1 expression and its immunobiology. In contrast, cell-intrinsic functional regulation not well understood. Here, we demonstrate induction of in melanoma cells via type I interferon (IFNAR) signaling reversal ICB efficacy through IFNAR pathway inhibition. Treatment with...
Abstract Monoclonal antibodies (abs) targeting the programmed cell death 1 (PD-1) immune checkpoint pathway have revolutionized tumor therapy. Because T-cell-directed PD-1 blockade boosts immunity, anti-PD-1 abs been developed for examining T-cell-PD-1 functions. More recently, expression has also reported directly on cancer cells of various etiology, including in melanoma. Nevertheless, there is a paucity studies validating ab clone utility specific assay types characterizing cell-intrinsic...